KZA
Click for more information
0.00% 8.0¢ kazia therapeutics limited

Ann: GBM Agile Update, page-57

  1. Slider19200000
    83 Posts.
    lightbulb Created with Sketch. 19
    clock Created with Sketch.
    02/08/22
    04:09
    Post #: 62866717
    This is really confusing as to why the final phase II results showed overall survival rate of 15.7 months and PFS of 8.6 months which the company said exceeds the standard of care? The AGILE study is saying otherwise?
    KZA Price at posting: 24.0¢ Sentiment: None Disclosure: Held
    Likes Created with Sketch.  Upvote
    lightbulb Created with Sketch.  Great analysis
    Stroke 3 Created with Sketch. Comments Created with Sketch. Reply

  2. Top Stories

 

Featured News

MYR Myer lobs proposed merger at major shareholder Premier Investments
right-arrow Created with Sketch.
LYC Lynas eyes first dysprosium, terbium HREE production in CY25
right-arrow Created with Sketch.
RMS Ramelius boosts WA gold portfolio with stake in Spartan
right-arrow Created with Sketch.
NEWS Tenant turnover: Reducing costs and revenue-loss
right-arrow Created with Sketch.
IMU Imugene doses first cancer patient in Oasis trial
right-arrow Created with Sketch.
NIM Nimy extends sulphide targets at Mons with new anomalies identified
right-arrow Created with Sketch.
watchlist Created with Sketch. Add KZA (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.